Can a triple attack shrink untreatable liver tumors?
NCT ID NCT04592029
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This trial is testing whether combining a procedure that blocks blood flow to tumors (TACE) with two drugs—sintilimab, which boosts the immune system, and bevacizumab, which cuts off tumor blood supply—can safely and effectively treat liver cancer that cannot be surgically removed. The study enrolls adults with intermediate or advanced liver cancer who have not had prior systemic therapy. Researchers are evaluating safety, tumor response, and survival outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of transcatheter arterial chemoembolization (TACE), sintilimab (an immunotherapy), and bevacizumab (a targeted therapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with liver cancer that cannot be removed by surgery, potentially slowing disease progression and extending survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, including immune-related reactions and bleeding risks from bevacizumab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510260, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new imaging agent could tell doctors which liver cancers will resist immunotherapy
- Can adding a fourth drug shrink large liver tumors that invade the portal vein?
- Can a Four-Drug cocktail tame inoperable liver cancer?
- Chemo-loaded microspheres aim to starve liver tumors from within
- New combo therapy aims to stop liver cancer in its tracks
- New combo therapy aims to shrink liver tumors in Hard-to-Treat patients